Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 205

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Cachexia and Sarcopenia: Emerging Syndromes of Importance in Dogs and Cats

Open access
Freeman, L.M.·2012·Journal of Veterinary Internal Medicine

Abstract

Cachexia is the loss of lean body mass (LBM) that affects a large proportion of dogs and cats with congestive heart failure (CHF), chronic kidney disease (CKD), cancer, and a variety of other chronic diseases. Sarcopenia, the loss of LBM that occurs with aging, is a related syndrome, although sarcopenia occurs in the absence of disease. As many of the diseases associated with muscle loss are more common in aging, cachexia and sarcopenia often are concurrent problems. Both cachexia and sarcopenia have important clinical implications because they are associated with increased morbidity and mortality. The pathophysiology of these 2 syndromes is complex and multifactorial, but recent studies have provided new information that has helped to clarify mechanisms and identify potential new targets for treatment. Newly identified mechanisms and pathways that mediate cachexia appear to act by increasing energy requirements, decreasing energy intake, impairing nutrient absorption, and causing metabolic alterations. Whereas cachexia and sarcopenia are important areas of research for drug development in people, they are only beginning to be recognized in veterinary medicine. Greater awareness and earlier diagnosis will help provide practical approaches to managing body weight and lean tissue in dogs and cats, as well as more directed targets for treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1939-1676.2011.00838.x

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 120

  1. Doehner, 2002, Cardiac cachexia in early literature: A review of research prior to Medline, Int J Cardiol, 85, 7, 10.1016/S0167-5273(02)00230-9 · DOI
  2. von Haehling, 2009, Cardiac cachexia: A systematic overview, Pharmacol Therapeut, 121, 227, 10.1016/j.pharmthera.2008.09.009 · DOI · Paper page
  3. Morley, 2006, Cachexia: Pathophysiology and clinical relevance, Am J Clin Nutr, 83, 735, 10.1093/ajcn/83.4.735 · DOI · Paper page
  4. Lowry, 2006, Modern Nutrition in Health and Disease, 1381
  5. Anker, 1997, Wasting as independent risk factor for mortality in chronic heart failure, Lancet, 349, 1050, 10.1016/S0140-6736(96)07015-8 · DOI · Paper page
  6. Anker, 2003, Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study, Lancet, 361, 1077, 10.1016/S0140-6736(03)12892-9 · DOI · Paper page
  7. Freeman, 1994, The nutrition implications of cardiac cachexia, Nutr Rev, 52, 340, 10.1111/j.1753-4887.1994.tb01358.x · DOI · Paper page
  8. Baez, 2007, A prospective investigation of the prevalence and prognostic significance of weight loss and changes in body condition in feline cancer patients, J Fel Med Surg, 9, 411, 10.1016/j.jfms.2007.02.005 · DOI
  9. Scarlett, 1998, Associations between body condition and disease in cats, J Am Vet Med Assoc, 212, 1725, 10.2460/javma.1998.212.11.1725 · DOI · Paper page
  10. Doria-Rose, 2000, Mortality rates and causes of death among emaciated cats, J Am Vet Med Assoc, 216, 347, 10.2460/javma.2000.216.347 · DOI
  11. Mallery, 1999, Factors contributing to the decision for euthanasia of dogs with congestive heart failure, J Am Vet Med Assoc, 214, 1201, 10.2460/javma.1999.214.08.1201 · doi:10.2460/javma.1999.214.08.1201
  12. Sullivan, 1990, Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure, Circulation, 81, 518, 10.1161/01.CIR.81.2.518 · DOI · Paper page
  13. Carvalho, 2010, Heart failure increases atrogin-1 and MuRF1 gene expression in skeletal muscle with fiber type-specific atrophy, J Mol Histol, 41, 81, 10.1007/s10735-010-9262-x · DOI
  14. Oreopoulos, 2010, Comparison of direct body composition assessment methods in patients with chronic heart failure, J Card Fail, 16, 867, 10.1016/j.cardfail.2010.06.416 · DOI
  15. Freeman, 1996, Letter to the editor, J Vet Intern Med, 10, 99, 10.1111/j.1939-1676.1996.tb02037.x · DOI
  16. Evans, 2008, Cachexia: A new definition, Clin Nutr, 27, 6, 10.1016/j.clnu.2008.06.013 · DOI · Paper page
  17. Fearon, 2011, Definition and classification of cancer cachexia: An international consensus, Lancet Oncol, 12, 489, 10.1016/S1470-2045(10)70218-7 · DOI · Paper page
  18. Swimmer, 2011, Evaluation of the 6-minute walk test in pet dogs, J Vet Intern Med, 25, 405, 10.1111/j.1939-1676.2011.0689.x · doi:10.1111/j.1939-1676.2011.0689.x
  19. Freeman, 1998, Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure, J Vet Intern Med, 12, 440, 10.1111/j.1939-1676.1998.tb02148.x · DOI
  20. Oreopoulos, 2008, Body mass index and mortality in heart failure: A meta-analysis, Am Heart J, 156, 13, 10.1016/j.ahj.2008.02.014 · DOI · Paper page
  21. Webster, 1984, The composition of excess weight in obese women estimated by body density, total body water and total body potassium, Hum Nutr Clin Nutr, 38, 299
  22. Wells, 2006, Body composition in normal weight, overweight and obese children: Matched case-control analyses of total and regional tissue masses, and body composition trends in relation to relative weight, Int J Obesity, 30, 1506, 10.1038/sj.ijo.0803402 · DOI
  23. Slupe, 2008, Association of body weight and body condition with survival in dogs with heart failure, J Vet Intern Med, 22, 561, 10.1111/j.1939-1676.2008.0071.x · DOI
  24. Finn, 2010, The relationship between body weight, body condition, and survival in cats with heart failure, J Vet Intern Med, 24, 1369, 10.1111/j.1939-1676.2010.0584.x · DOI
  25. Tisdale, 2009, Mechanisms of cancer cachexia, Physiol Rev, 89, 381, 10.1152/physrev.00016.2008 · DOI · Paper page
  26. Michel, 2004, Evaluation of body condition and weight loss in dogs presented to a veterinary oncology service, J Vet Intern Med, 18, 692, 10.1111/j.1939-1676.2004.tb02607.x · DOI
  27. Weeth, 2007, Prevalence of obese dogs in a population of dogs with cancer, Am J Vet Res, 68, 389, 10.2460/ajvr.68.4.389 · DOI
  28. Laflamme, 1997, Development and validation of a body condition score system for dogs, Canine Pract, 22, 10
  29. Laflamme, 1997, Development and validation of a body condition score system for cats, Feline Pract, 25, 13
  30. Glanton, 2003, Factors associated with improved short term survival in obese end stage renal disease patients, Ann Epidemiol, 13, 136, 10.1016/S1047-2797(02)00251-X · DOI
  31. Fleischmann, 1999, Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients, Kidney Int, 55, 1560, 10.1046/j.1523-1755.1999.00389.x · DOI · Paper page
  32. Kovesdy, 2007, Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis, Am J Kidney Dis, 49, 581, 10.1053/j.ajkd.2007.02.277 · DOI · Paper page
  33. Kalantar-Zadeh, 2010, The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis, Mayo Clinic Proc, 85, 991, 10.4065/mcp.2010.0336 · DOI · Paper page
  34. Abbott, 2004, Body mass index, dialysis modality, and survival: Analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study, Kidney Int, 65, 597, 10.1111/j.1523-1755.2004.00385.x · DOI · Paper page
  35. Port, 2002, Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients, J Am Soc Nephrol, 13, 1061, 10.1681/ASN.V1341061 · DOI · Paper page
  36. Leavey, 1998, Simple nutritional indicators as independent predictors of mortality in hemodialysis patients, Am J Kidney Dis, 31, 997, 10.1053/ajkd.1998.v31.pm9631845 · DOI · Paper page
  37. Leavey, 2001, Body mass index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS), Nephrol Dial Transplant, 16, 2386, 10.1093/ndt/16.12.2386 · DOI · Paper page
  38. Wolfe, 2000, Body size, dose of hemodialysis, and mortality, Am J Kidney Dis, 35, 80, 10.1016/S0272-6386(00)70305-2 · DOI · Paper page
  39. Kopple, 1999, Body weight-for-height relationships predict mortality in maintenance hemodialysis patients, Kidney Int, 56, 1136, 10.1046/j.1523-1755.1999.00615.x · DOI · Paper page
  40. Johansen, 2004, Association of body size with outcomes among patients beginning dialysis, Am J Clin Nutr, 80, 324, 10.1093/ajcn/80.2.324 · DOI · Paper page
  41. Lowrie, 2002, Body size, dialysis dose and death risk relationships among hemodialysis patients, Kidney Int, 62, 1891, 10.1046/j.1523-1755.2002.00642.x · DOI
  42. Kaizu, 1998, Overweight as another nutritional risk factor for the long-term survival of non-diabetic hemodialysis patients, Clin Nephrol, 50, 44
  43. Parker, Association between body condition and survival in dogs with acquired chronic kidney disease, 10.1111/j.1939-1676.2011.00805.x · DOI
  44. Escalante, 2005, Paradoxical effect of body mass index on survival in rheumatoid arthritis: Role of comorbidity and systemic inflammation, Arch Intern Med, 165, 1624, 10.1001/archinte.165.14.1624 · DOI · Paper page
  45. Roubenoff, 2009, Rheumatoid cachexia: A complication of rheumatoid arthritis moves into the 21st century, Arthritis Res Therapy, 11, 108, 10.1186/ar2658 · DOI
  46. Marti, 2006, Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy, Eur Resp J, 27, 689, 10.1183/09031936.06.00076405 · DOI
  47. Wanke, 2004, Collaborative recommendations: The approach to diagnosis and treatment of HIV wasting, JAIDS, 37, S284
  48. Biggs, 2010, Association between adiposity in midlife and older age and risk of diabetes in older adults, J Am Med Assoc, 303, 2504, 10.1001/jama.2010.843 · DOI
  49. Lang, 2009, Sarcopenia: Etiology, clinical consequences, intervention, and assessment, Osteoporosis Int, 21, 543, 10.1007/s00198-009-1059-y · DOI · Paper page
  50. Meyer, 1980, Nutrition of the Dog and Cat, 15
  51. Lawler, 2009, Diet restriction and ageing in the dog: Major observations over two decades, Br J Nutr, 99, 793, 10.1017/S0007114507871686 · DOI · Paper page
  52. Toth, 1997, Daily energy requirements in heart failure patients, Metabolism, 46, 1294, 10.1016/S0026-0495(97)90233-X · DOI
  53. Riley, 1991, Resting energy expenditure in chronic cardiac failure, Clin Sci, 80, 633, 10.1042/cs0800633 · DOI
  54. Ogilvie, 1996, Resting energy expenditure in dogs with nonhematopoietic malignancies before and after excision of tumors, Am J Vet Res, 57, 1463, 10.2460/ajvr.1996.57.10.1463 · DOI
  55. Freeman, 2003, Evaluation of dietary patterns in dogs with cardiac disease, J Am Vet Med Assoc, 223, 1301, 10.2460/javma.2003.223.1301 · doi:10.2460/javma.2003.223.1301
  56. Torin, 2007, Dietary patterns of cats with cardiac disease, J Am Vet Med Assoc, 230, 862, 10.2460/javma.230.6.862 · DOI
  57. Woods, 2008, Central control of body weight and appetite, J Clin Endocrinol Metab, 93, S37, 10.1210/jc.2008-1630 · DOI · Paper page
  58. Laviano, 2008, Neural control of the anorexia-cachexia syndrome, Am J Physiol Endocrinol Metab, 295, E1000, 10.1152/ajpendo.90252.2008 · DOI
  59. Schwenke, 2008, Early ghrelin treatment after myocardial infarction prevents an increase in cardiac sympathetic tone and reduces mortality, Endocrinology, 149, 5172, 10.1210/en.2008-0472 · DOI
  60. Deboer, 2008, Ghrelin treatment of chronic kidney disease: Improvements in lean body mass and cytokine profile, Endocrinology, 149, 827, 10.1210/en.2007-1046 · DOI
  61. DeBoer, 2008, Emergence of ghrelin as a treatment for cachexia syndromes, Nutrition, 24, 806, 10.1016/j.nut.2008.06.013 · DOI
  62. Lund, 2009, Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation, Eur J Heart Fail, 11, 789, 10.1093/eurjhf/hfp088 · DOI
  63. Nagaya, 2001, Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure, Circulation, 104, 1430, 10.1161/hc3601.095575 · DOI · Paper page
  64. Nagaya, 2004, Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure, Circulation, 110, 3674, 10.1161/01.CIR.0000149746.62908.BB · DOI · Paper page
  65. Akashi, 2009, No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure, Int J Cardiol, 137, 267, 10.1016/j.ijcard.2008.06.094 · DOI
  66. Nagaya, 2005, Treatment of cachexia with ghrelin in patients with COPD, Chest, 128, 1187, 10.1378/chest.128.3.1187 · DOI · Paper page
  67. Strassburg, 2008, Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats, Am J Physiol Endocrinol Metab, 295, E78, 10.1152/ajpendo.00040.2008 · DOI
  68. Hamid, 2009, Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: Role of nuclear factor-kappaB and inflammatory activation, Circulation, 119, 1386, 10.1161/CIRCULATIONAHA.108.802918 · DOI · Paper page
  69. Moresi, 2008, Tumor necrosis factor-alpha inhibition of skeletal muscle regeneration is mediated by a caspase-dependent stem cell response, Stem Cells, 26, 997, 10.1634/stemcells.2007-0493 · DOI
  70. Anker, 2002, How to recover from renaissance? The significance of the results of recover, renaissance, renewal and attach, Int J Cardiol, 86, 123, 10.1016/S0167-5273(02)00470-9 · DOI · Paper page
  71. Marcora, 2006, Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis, Am J Clin Nutr, 84, 1463, 10.1093/ajcn/84.6.1463 · DOI · Paper page
  72. Wiese, 2008, Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy, Nutr Clin Pract, 23, 551, 10.1177/0884533608323421 · DOI
  73. Meurs, 2002, Plasma concentrations of tumor necrosis factor-alpha in cats with congestive heart failure, Am J Vet Res, 63, 640, 10.2460/ajvr.2002.63.640 · DOI
  74. Sheth, 2002, Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure, Am J Cardiol, 90, 496, 10.1016/S0002-9149(02)02521-3 · DOI
  75. Matsumori, 1997, Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: A possible mechanism for its effect in heart failure, Circulation, 96, 1386, 10.1161/01.CIR.96.5.1386 · DOI
  76. Parissis, 2004, Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure, Am J Cardiol, 93, 1309, 10.1016/j.amjcard.2004.01.073 · DOI · Paper page
  77. Molenaar, 2006, Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting, Br J Pharmacol, 147, 583, 10.1038/sj.bjp.0706670 · DOI
  78. Yu, 2008, Fiber type-specific nitric oxide protects oxidative myofibers against cachectic stimuli, PLoS ONE, 3, e2086, 10.1371/journal.pone.0002086 · DOI
  79. Lenk, 2009, Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model, Eur J Heart Fail, 11, 342, 10.1093/eurjhf/hfp020 · DOI
  80. McFarlane, 2006, Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism, J Cell Physiol, 209, 501, 10.1002/jcp.20757 · DOI · Paper page
  81. Gruson, 2011, Increased plasma myostatin in heart failure, Eur J Heart Fail, 13, 734, 10.1093/eurjhf/hfr024 · DOI
  82. Kambadur, 1997, Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle, Genome Res, 7, 910, 10.1101/gr.7.9.910 · DOI · Paper page
  83. Grobet, 1997, A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle, Nat Genet, 17, 71, 10.1038/ng0997-71 · DOI · Paper page
  84. Zimmers, 2002, Induction of cachexia in mice by systemically administered myostatin, Science, 296, 1486, 10.1126/science.1069525 · DOI · Paper page
  85. Benny Klimek, 2010, Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia, Biochem Biophys Res Comm, 391, 1548, 10.1016/j.bbrc.2009.12.123 · DOI · Paper page
  86. Zhou, 2010, Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival, Cell, 142, 531, 10.1016/j.cell.2010.07.011 · DOI · Paper page
  87. Whittemore, 2003, Inhibition of myostatin in adult mice increases skeletal muscle mass and strength, Biochem Biophys Res Comm, 300, 965, 10.1016/S0006-291X(02)02953-4 · DOI · Paper page
  88. Siriett, 2007, Antagonism of myostatin enhances muscle regeneration during sarcopenia, Mol Ther: J Am Soc Gene Ther, 15, 1463, 10.1038/sj.mt.6300182 · DOI
  89. Dalla Libera, 2010, Skeletal muscle proteins oxidation in chronic right heart failure in rats: Can different beta-blockers prevent it to the same degree?, Int J Cardiol, 143, 192, 10.1016/j.ijcard.2009.02.012 · DOI
  90. Hryniewicz, 2007, Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure, J Card Fail, 9, 464, 10.1016/S1071-9164(03)00582-7 · DOI
  91. Lainscak, 2006, Body composition changes in patients with systolic heart failure treated with beta blockers: A pilot study, Int J Cardiol, 106, 319, 10.1016/j.ijcard.2005.01.061 · DOI
  92. Vaz Perez, 2010, The relationship between tumor necrosis factor-alpha, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure, Int J Cardiol, 141, 39, 10.1016/j.ijcard.2008.11.146 · DOI
  93. McEntegart, 2007, Increase in serum adiponectin concentration in patients with heart failure and cachexia: Relationship with leptin, other cytokines, and B-type natriuretic peptide, Eur Heart J, 28, 829, 10.1093/eurheartj/ehm033 · DOI
  94. Lafontan, 2005, An unsuspected metabolic role for atrial natriuretic peptides: The control of lipolysis, lipid mobilization, and systemic nonesterified fatty acids levels in humans, Arterioscler Thromb Vasc Biol, 25, 2032, 10.1161/01.ATV.0000183728.14712.d8 · DOI
  95. Doehner, 2001, Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia, Eur J Endocrinol, 145, 727, 10.1530/eje.0.1450727 · DOI
  96. Fonfara, 2011, Leptin expression in dogs with cardiac disease and congestive heart failure, J Vet Intern Med, 25, 1017, 10.1111/j.1939-1676.2011.00782.x · DOI
  97. Laoutaris, 2009, High plasma adiponectin is related to low functional capacity in patients with chronic heart failure, Int J Cardiol, 144, 230, 10.1016/j.ijcard.2008.12.126 · DOI
  98. Wolf, 2006, Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients, Cancer, 106, 966, 10.1002/cncr.21690 · DOI · Paper page
  99. Smiechowska, 2010, Adipokines in patients with cancer anorexia and cachexia, J Invest Med, 58, 554, 10.2310/JIM.0b013e3181cf91ca · DOI
  100. Kerem, 2008, Adipokines and ghrelin in gastric cancer cachexia, World J Gastroenterol, 14, 3633, 10.3748/wjg.14.3633 · DOI
  101. Penna, 2010, Muscle atrophy in experimental cancer cachexia: Is the IGF-1 signaling pathway involved?, Int J Cancer, 127, 1706, 10.1002/ijc.25146 · DOI
  102. Petretta, 2007, NT-proBNP, IGF-I and survival in patients with chronic heart failure, Growth Horm IGF Res, 17, 288, 10.1016/j.ghir.2007.01.020 · DOI
  103. Gotherstrom, 2007, A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults, J Clin Endocrinol Metab, 92, 1442, 10.1210/jc.2006-1487 · DOI
  104. Rosenthal, 2002, Gene therapy for cardiac cachexia?, Int J Cardiol, 85, 185, 10.1016/S0167-5273(02)00253-X · DOI
  105. Rojas Vega, 2010, Effect of resistance exercise on serum levels of growth factors in humans, Horm Metab Res, 42, 982, 10.1055/s-0030-1267950 · DOI
  106. Fearon, 2008, Cancer cachexia: Developing multimodal therapy for a multidimensional problem, Eur J Cancer, 44, 1124, 10.1016/j.ejca.2008.02.033 · DOI · Paper page
  107. Baldwin, 2010, AAHA nutritional assessment guidelines for dogs and cats, J Am Anim Hosp Assoc, 46, 285, 10.5326/0460285 · DOI · Paper page
  108. WSAVA Nutritional Assessment Guidelines Task Force Members, 2011, Nutritional assessment guidelines, J Small Anim Pract, 52, 385, 10.1111/j.1748-5827.2011.01079.x · DOI · Paper page
  109. Buffington, Indoor pet initiative
  110. Association of American Feed Control Officials, 2011, Official Publication
  111. Hutchinson, 2011, Survey of opinions about nutritional requirements of senior dogs and analysis of nutrient profiles of commercially available diets for senior dogs, Int J Appl Res Vet Med, 9, 68
  112. Lana, 2006, The use of complementary and alternative therapies in dogs and cats with cancer, J Am Anim Hosp Assoc, 42, 361, 10.5326/0420361 · doi:10.5326/0420361
  113. American College of Veterinary Nutrition website
  114. Delaney, 2011, How a diplomate of the American College of Veterinary Nutrition can help your practice and patients, Compend Contin Educ Vet, 33, E1
  115. Smith, 2007, Omega-3 fatty acids in Boxer dogs with arrhythmogenic right ventricular cardiomyopathy, J Vet Intern Med, 21, 265, 10.1111/j.1939-1676.2007.tb02959.x · doi:10.1111/j.1939-1676.2007.tb02959.x
  116. Freeman, 2010, Beneficial effects of omega-3 fatty acids in cardiovascular disease, J Small Anim Pract, 51, 462, 10.1111/j.1748-5827.2010.00968.x · DOI
  117. Bauer, 2007, Responses of dogs to dietary omega-3 fatty acids, J Am Vet Med Assoc, 231, 1657, 10.2460/javma.231.11.1657 · DOI
  118. Glover, 2010, Resistance exercise and appropriate nutrition to counteract muscle wasting and promote muscle hypertrophy, Curr Opin Clin Nutr Metab Care, 13, 630
  119. Cheema, 2007, Randomized controlled trial of intradialytic resistance training to target muscle wasting in ESRD: The Progressive Exercise for Anabolism in Kidney Disease (PEAK) study, Am J Kid Dis, 50, 574, 10.1053/j.ajkd.2007.07.005 · DOI
  120. Schulze, 2002, Chronic heart failure and skeletal muscle catabolism: Effects of exercise training, Int J Cardiol, 85, 141, 10.1016/S0167-5273(02)00243-7 · DOI

Cited by

See all 205

Metadata

Authors
Freeman, L. M.
Venue
Journal of Veterinary Internal Medicine
Published
2012-01-01
Volume
26
Issue
1
Pages
3-17
ISSN
  • 0891-6640 (ISSN-L)
  • 1939-1676
OpenAlex
W2157868418
Cited by
205
References
15
FWCI
2.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cachexia and Sarcopenia: Emerging Syndromes of Importance in Dogs and Cats. https://app.cochat.ai/papers/10.1111/j.1939-1676.2011.00838.x
The paper
Freeman, L. M. (2012). Cachexia and Sarcopenia: Emerging Syndromes of Importance in Dogs and Cats. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/j.1939-1676.2011.00838.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.